Stem Cell Therapy for Doberman Pinschers with Dilated Cardiomyopathy
Dilated cardiomyopathy (DCM) is a fairly common and fatal disease in the Doberman pinscher. Once heart failure has occurred, treatment is symptomatic and palliative.
Stem cell therapy may be a promising strategy for improving cardiac function, rather than just providing palliative care.
The purpose of this study is to pilot the use of canine heart stem cells to improve the outcome in dogs with DCM. We have previously shown these cells to be safe and effective in humans who have suffered heart attacks, as well as in other experimental animals. Our hope is that this study will ultimately lead to better treatments for dogs with DCM, and to improve both quality of life and lifespan.
A small blood sample for genetic testing. If a copy of the mutation is present, we will as your pet to come back for a thorough clinical evaluation including cardiac ultrasound and 24hr ECG that your dog will wear home. The monitor may be removed after 24 hours by the owner or at the NCSU-CVM.
- Doberman pinschers with DCM with a fractional shortening of < 20% by echocardiography (or suspected of having DCM if not yet diagnosed.
- History of cancer
- Other non-cardiovascular disease with life expectancy of < 1 year
- Active uncontrolled infection
- History of treatment with immunosuppressive agents, including chronic systemic
corticosteroids, biologic agents targeting the immune system, anti-tumor and anti-neoplastic drugs or anti-VEGF within 6 months prior to enrollment.
Owners will be expected to cover the cost of initial diagnosis and work up, but the cost of the stem cell treatment and 1 year of follow-up evaluations (including 3 echocardiograms at Month 1, Month 2, and Month 6) will be paid by the study.
Clinical Studies Core Lab: 919.515.2633 or 919.513.6384 or email@example.com
Page last updated July 25, 2014